Drug Database
DI

dihydroartemisinin + piperaquine (ACT, MMV / ACT, Pfizer / Eurartesim)

✓ Approved

Pierre Fabre S.A. · 小分子 · 小分子

什么是 dihydroartemisinin + piperaquine?

dihydroartemisinin + piperaquine 是一种小分子,由Pierre Fabre S.A.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名ACT, MMV, ACT, Pfizer, Eurartesim
公司Pierre Fabre S.A.
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

dihydroartemisinin + piperaquine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsPlasmodium malariae infection✓ Approved

相关研究文献

PubMedCurrent medicinal chemistry2026-11-18

Dihydroartemisinin Suppresses Colorectal Cancer Growth in Association with JAK2/STAT3 Signalling Modulation.

Huang Ju J, Zhang Yukun Y, Luo Jun J, Shi Zhengda Z et al.

Dihydroartemisinin (DHA), an active derivative of artemisinin, has anti-tumour potential, but its immunomodulatory effects in Colorectal Cancer (CRC) remain insufficiently defined. We investigated whether DHA suppresses CRC phenotypes in association with JAK2/STAT3 inhibition and altered immune-checkpoint- marker expression. HCT116 and RKO CRC cells were evaluated using CCK-8, colony formation, wound healing, Transwell migration, live/dead staining, qRT-PCR, western blotting, and pharmacological rescue assays. A total of 20 male C57BL/6 mice (6-8 weeks old; 22-25 grams) with AOM/DSS-induced CRC were allocated to control and DHA-treatment groups (n = 10 per group) to assess tumour burden, pathway-associated markers, checkpoint-marker expression and CD8+ cell presence in tumour tissue. DHA inhibited CRC cell proliferation and migration and promoted apoptosis, as indicated by reduced Bcl-2 and increased cleaved caspase-3. DHA reduced JAK2/STAT3 signalling and PD-L1/CD47 expression; these effects were partly counteracted by Coumermycin A1. in vivo, DHA reduced tumour burden, improved histological differentiation, reduced Ki-67, JAK2/STAT3, PD-L1 and CD47 staining, and was associated with increased intratumoural CD8+ cell staining. The findings support an association between DHA treatment and reduced JAK2/STAT3 signalling, lower immune-evasion marker expression, and increased CD8+ cell presence; functional activation of CD8+ cells was not directly assessed. DHA suppresses CRC progression in the models studied and modulates JAK2/STAT3-associated immune-evasion markers. These data support further preclinical evaluation of DHA as a potential adjunctive strategy for CRC.

PMID 43048835
阅读全文 →
PubMedEuropean journal of immunology2026-11-16

Dihydroartemisinin Acetal Dimer Suppresses Th1/Th17-Mediated Pro-Inflammatory Axis to Mitigate EAE.

Lv Jie J, Wan Gen G, Luo Jing J, Jiang Xiangrui X et al.

Multiple sclerosis (MS) is a central nervous system (CNS)-specific chronic disorder, characterized by T cell-mediated demyelination and neuroinflammation. Dihydroartemisinin, a semisynthetic artemisinin derivative, has been reported as a potential MS treatment for its immunomodulatory activity. This work investigated dihydroartemisinin acetal dimer (DHAAD), a novel dihydroartemisinin derivative, for MS therapy and explored possible mechanistic insights. A library of 14 small-molecule compounds was screened through in vitro Th1/Th17 differentiation assays. Experimental autoimmune encephalomyelitis (EAE), an animal model for MS, was induced in mice with the MOG35 - 55 peptide. The compound identified through screening was orally administered to mice at various doses. Its therapeutic effects at the tissue and cellular levels were assessed using histopathological analysis and flow cytometry, respectively, while the effects on cytokine levels and signature gene expression were evaluated through enzyme-linked immunosorbent assay and quantitative polymerase chain reaction, respectively. DHAAD was identified as effectively inhibiting Th1/Th17 cell differentiation. DHAAD treatment mitigated EAE manifestations in mice (reduced clinical scores, leukocyte infiltration, and CNS demyelination) and suppressed Th1/Th17 cell populations in both CNS and peripheral compartments, concurrently reducing IFN-γ and IL-17A secretion. Upon MOG35 - 55 re-stimulation, splenocytes and lymph node cells from treated mice also exhibited decreased IFN-γ and IL-17A production. Furthermore, DHAAD administration downregulated the genes driving Th1/Th17 cell differentiation and those executing their pro-inflammatory functions. DHAAD alleviates EAE symptoms by suppressing pro-inflammatory Th1/Th17 differentiation pathways through its immunosuppressive effects in the CNS and peripheral sites, thereby ameliorating inflammation and revealing its application potential in MS.

PMID 43036947
阅读全文 →
PubMedFrontiers in immunology2026-11-13

Dihydroartemisinin as a pharmacokinetically constrained immune-conditioning pulse in cancer therapy.

Wei Pei P, Wang Jiahua J, Cao Yuan Y, Song Yongxiang Y et al.

Mechanistic assignment in cancer immunology often assumes that durable antitumor effects reflect sustained pharmacologic pressure on tumor cells. Dihydroartemisinin (DHA) provides a useful test case for revisiting this assumption because clinically achievable systemic exposure is brief and free-drug availability is constrained by substantial protein binding. We therefore propose that brief systemic DHA exposure may act as a pharmacokinetically constrained immune-conditioning pulse whose durable antitumor effects, when present, could involve persistent tumor-intrinsic injury, immune relay, or both. Within this framework, transient tumor or stromal stress may be converted into longer-lived antitumor activity through myeloid-state transition, dendritic-cell activation, relief of immune exclusion, and subsequent CD8+ T-cell priming. Current evidence does not yet establish a dominant immune mechanism under exposure-matched conditions. Suppressive myeloid-state change, a tumor stress-dendritic cell-CD8+ T-cell axis, and direct lymphocyte responsiveness are competing hypotheses for exposure-matched testing alongside direct tumor-cell effects. This framework informs exposure-matched experimental design, biomarker development, and rational immunotherapy combinations, and provides a falsifiable prioritization scheme based on exposure matching, temporal precedence, persistence after washout, and in vivo necessity.

PMID 43022162
阅读全文 →
PubMedZhonghua nan ke xue = National journal of andrology2026-11-11

[Dihydroartemisinin inhibiting the progression of castration resistant prostate cancer through transcription factor MAFB].

Huo Jianwu J, Zhang Fulei F, Ma Hui H, Ren Zhaofeng Z et al.

Objective The prognosis of castration resistant prostate cancer (CRPC) is poor, and there is an urgent need to find new targets and drugs. Methods GSE32269 dataset was downloaded from the Gene Expression Omnibus Database (GEO), which included 51 prostate cancer samples and 4 tumor-free specimens. The prostate cancer samples included 22 cases of hormone sensitive prostate cancer (HSPC) and 29 cases of CRPC. Differentially expressed genes were screened through bioinformatics analysis, followed by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Enrichment Analysis (GSEA). Subsequently, differential expression of transcription factor musculoaponeurotic fibrosarcoma oncogene homolog B(MAFB) was detected by immunohistochemistry, and the cellular function of MAFB was assessed through cell experiments. Finally, CRPC cells were treated with dihydroartemisinin (DHA), and the expression of MAFB as well as its effects on cellular functions were examined. Results Compared with HSPC tissues, a total of 849 differentially expressed genes were identified in CRPC tissues, among which 392 were up-regulated and 457 were down-regulated. Gene enrichment analysis suggested that the CRPC gene was associated with extracellular matrix secretion, epithelial mesenchymal transition and glycolysis. Further investigation revealed that knocking down the expression of MAFB reduced cell proliferation and migration ability, while increasing the level of cell apoptosis. After DHA treatment, the expression level of MAFB decreased in CRPC cells, along with reduced proliferative capacity and increased apoptosis. Conclusion DHA may inhibit the progression of CRPC by regulating the transcription factor MAFB, suggesting its potential as a therapeutic agent for CRPC.

PMID 43012189
阅读全文 →
PubMedMalaria journal2026-11-05

From near-elimination to resurgence: a comparative analysis of two mass drug administration campaigns on Grande Comore Island (2013-2024).

Li Mingqiang M, Yuan Yueming Y, Zhang Hongying H, Lu Chenguang C et al.

Mass drug administration (MDA) achieved sustained malaria elimination on Mohéli and Anjouan but only transient control on Grande Comore. Following resurgence from 1061 cases in 2015 to 19,453 in 2018, a renewed MDA campaign was implemented on Grande Comore in 2019. This study evaluates its effectiveness compared to the 2013 campaign to identify determinants of sustained suppression. Two rounds of artemisinin‑piperaquine plus single low‑dose primaquine were administered in September-October 2019, targeting 348,961 residents. MDA coverage, adverse events, and parasitological outcomes from surveys at four time points were assessed. Monthly confirmed cases from 2012-2024 were analyzed descriptively to compare the epidemiological trajectories following the 2013 and 2019 campaigns, acknowledging that this historical comparison with multiple co‑varying confounders does not permit causal attribution. Round 1 coverage was 83.5%, declining to 58.0% in Round 2 (p = 0.0008). Adverse events occurred in 0.3% of doses, with no severe events reported. Parasitemia declined by 92.7% after Round 1 and remained 96.5% below baseline at 15 months. Reported monthly cases declined by 79.7% from the pre‑MDA mean (1,731 cases/month) to the early post‑MDA mean (352 cases/month), reaching a nadir of 192 cases in April 2020-an 88.2% reduction from baseline (1,621 cases/month). However, this nadir coincided with the first COVID‑19 lockdown, which likely reduced healthcare access and reporting completeness. Cases remained below the 50% threshold (810 cases/month) for 19 consecutive months but rebounded to 53.7% above baseline by 2022-2024. In descriptive comparison with the 2013 campaign (99.1% reduction, > 48 months suppression), the 2019 campaign showed a lower reduction (88.2%) and shorter suppression duration (19 months). Spatially, resurgence after the 2013 campaign was relatively focal, while after the 2019 campaign it became more widespread-a pattern consistent with a larger or more dispersed residual parasite reservoir. The 2019 MDA was followed by less durable suppression than observed after the 2013 campaign. Declining second‑round coverage, weaker post‑MDA surveillance, and COVID‑19‑related disruptions may have contributed, but the historical comparison involves multiple confounders and precludes causal attribution. These findings should be interpreted as hypothesis‑generating for future malaria elimination strategies. Trial registration The study protocol was approved by the National Health Ethics Committee of the Union of Comoros (No. 12521/MSSPG/CAB) on 13 September 2012, the Guangzhou University of Chinese Medicine Ethics Committee for Health Research (No. 2012L0816) on 25 September 2012, and the Ethical Board of Guangdong Provincial Hospital of Chinese Medicine (No. BF2019-169-01) on 18 October 2019.

PMID 42983746
阅读全文 →
PubMedRSC advances2026-11-03

Pd-catalyzed, oxidant-promoted, chelation-assisted, regioselective direct ortho-nitration of 1-aryl-1H-indazoles via C-H bond activation: direct access to novel indazole-based antiproliferative agents.

Sen Janmejaya J, Shivani, Kumar Pushpendra P, Datusalia Ashok Kumar AK et al.

Herein, we developed a highly efficient palladium-catalyzed, oxidant-promoted, chelation-assisted, regioselective strategy to introduce the nitro group directly at the ortho-position of the pendant aryl ring of the 1-aryl-1H-indazoles. The newly developed methodology is bench-stable and exclusively furnishes the C2' (ortho)-substituted 1-(2-nitroaryl)-1H-indazoles 2a-z/2aa-ad in up to 87% yield. The nitrated product serves as a versatile precursor and is reduced to a key amine functionality, which paves the path for several transformed pharmacologically and medicinally relevant derivatives, such as sulfonamide, N-benzylated compound, amide, thiourea, etc. To shed light on the underlying mechanistic pathway, several control experiments were conducted. The free-radical scavengers (TEMPO and BHT) successfully trapped the in situ formed free radical in the reaction mixture, and the TEMPO-nitro adduct was detected by HRMS analysis, thereby confirming the involvement of the free-radical pathway in our developed protocol. The key features of this methodology involve an operationally simple regioselective protocol, a wide substrate scope, excellent functional group tolerance, high yields, scalable gram-scale synthesis, and direct access to N-containing congeners via post-functional modifications. Furthermore, the antiproliferative activity of selected derivatives has been evaluated against the human glioblastoma U-87 MG cancer cell line. Among the tested derivatives, compound 2k exhibited the most potent antiproliferative activity against the cancer cells, with an IC50 value of 51.99 ± 14.96 µM compared to the standard drug dihydroartemisinin (DHA) 80.44 ± 7.5 µM.

PMID 42974101
阅读全文 →

注册免费账户还可查看另外 3082 篇文献

免费注册查看全部文献 →

了解更多dihydroartemisinin + piperaquine